SPX-303

· SparX Biotech (Jiangsu) Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SPX-303, covering 2024-09-24 to 2024-09-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors [Phase 1]